CytoSorbents Has Submitted Its DrugSorb-ATR Medical Device De Novo Marketing Application To The FDA, To Reduce Severity Of Perioperative Bleeding In Patients On Ticagrelor (Brilinta, AstraZeneca) Undergoing Coronary Artery Bypass Graft Surgery
CytoSorbents Has Submitted Its DrugSorb-ATR Medical Device De Novo Marketing Application To The FDA, To Reduce Severity Of Perioperative Bleeding In Patients On Ticagrelor (Brilinta, AstraZeneca) Undergoing Coronary Artery Bypass Graft Surgery
cytosorbents已向FDA提交了其DrugSorb-ATR器械De Novo營銷申請，以減輕接受冠狀動脈旁路移植手術的Ticagrelor（Brilinta，阿斯利康）患者圍手術期出血的嚴重程度
CytoSorbents Has Submitted Its DrugSorb-ATR Medical Device De Novo Marketing Application To The FDA, To Reduce Severity Of Perioperative Bleeding In Patients On Ticagrelor (Brilinta, AstraZeneca) Undergoing Coronary Artery Bypass Graft Surgery
cytosorbents已向FDA提交了其DrugSorb-ATR器械De Novo營銷申請，以減輕接受冠狀動脈旁路移植手術的Ticagrelor（Brilinta，阿斯利康）患者圍手術期出血的嚴重程度
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間